Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.

By A. Nakamizo, F. Marini, T. Amano, M. Studeny, J. Gumin, Julianne J Chen, S. Hentschel, G. Vecil, J. Dembinski, Michael Andreeff and 1 more. Cancer Research, 2005

1,067 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/6d4870e5d16c4f10769711c7e8773a6817e0d7a8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Aline M. Betancourt
2. Ruth S. Waterman
3. Suzanne L. Tomchuck
4. Sarah L. Henkle
5. D. Hanahan
6. Lisa M. Coussens
7. Maria Ester Bernardo
8. W. Fibbe

In Immunology

1. Aline M. Betancourt
2. Ruth S. Waterman
3. Suzanne L. Tomchuck
4. Sarah L. Henkle
5. W. Fibbe
6. Maria Ester Bernardo

In Oncology

1. Lisa M. Coussens
2. D. Hanahan

Citations in the corpus

• A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype (2010, background): “Numerous investigators have now demonstrated the successful recruitment and multi-organ engraftment capability of infused MSCs in various animal models and human clinical trials [6]–[10].”
• Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression (2009, background): “In those and subsequent studies, we demonstrated that MSC, administered intravenously, were able to integrate and persist within tumor stroma of pre-established human melanoma, breast cancer and glioma xenografts [11,12,16].”
• Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs (2019, background): “Furthermore, MSCs seem to have a distinct tropism for tumors as BM-MSCs were shown to accumulate in brain tumors after intracarotid injection, whereas fibroblasts and U87 glioma cells did not (20).”